Tyra Biosciences Inc. (TYRA)
8.71
-0.59 (-6.34%)
At close: Apr 01, 2025, 3:59 PM
8.43
-3.30%
After-hours: Apr 01, 2025, 06:06 PM EDT
-6.34% (1D)
| Bid | 8.19 |
| Market Cap | 442.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.51 |
| PE Ratio (ttm) | -5.77 |
| Forward PE | -7.78 |
| Analyst | Buy |
| Ask | 8.93 |
| Volume | 669,109 |
| Avg. Volume (20D) | 285,338 |
| Open | 9.21 |
| Previous Close | 9.30 |
| Day's Range | 8.68 - 9.41 |
| 52-Week Range | 8.68 - 29.60 |
| Beta | 1.09 |
About TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondro...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2021
Employees 60
Stock Exchange NASDAQ
Ticker Symbol TYRA
Website https://www.tyra.bio
Analyst Forecast
According to 6 analyst ratings, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is $30.5, which is an increase of 249.97% from the latest price.
Stock Forecasts5 months ago
-23.35%
Tyra Biosciences shares are trading lower. The com...
Unlock content with
Pro Subscription
